Systematic benchmarking of nanopore Q20+ kit in SARS-CoV-2 whole genome sequencing

• Published in: Frontiers in microbiology 2022-10, Vol.13, p.973367-973367
• Main Authors: Luo, Junhong, Meng, Zixinrong, Xu, Xingyu, Wang, Lei, Zhao, Kangchen, Zhu, Xiaojuan, Qiao, Qiao, Ge, Yiyue, Mao, Lingfeng, Cui, Lunbiao
• Format: Article
• Language: English
• Subjects: accuracy; coronavirus; Microbiology; nanopore sequencing; Q20+ kit; SARS-CoV-2
• ISSN: 1664-302X; 1664-302X
• DOI: 10.3389/fmicb.2022.973367

Whole genome sequencing provides rapid insight into key information about the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), such as virus typing and key mutation site, and this information is important for precise prevention, control and tracing of coronavirus disease 2019 (COVID-19) outbreak in conjunction with the epidemiological information of the case. Nanopore sequencing is widely used around the world for its short sample-to-result time, simple experimental operation and long sequencing reads. However, because nanopore sequencing is a relatively new sequencing technology, many researchers still have doubts about its accuracy. The combination of the newly launched nanopore sequencing Q20+ kit (LSK112) and flow cell R10.4 is a qualitative improvement over the accuracy of the previous kits. In this study, we firstly used LSK112 kit with flow cell R10.4 to sequence the SARS-CoV-2 whole genome, and summarized the sequencing results of the combination of LSK112 kit and flow cell R10.4 for the 1200bp amplicons of SARS-CoV-2. We found that the proportion of sequences with an accuracy of more than 99% reached 30.1%, and the average sequence accuracy reached 98.34%, while the results of the original combination of LSK109 kit and flow cell R9.4.1 were 0.61% and 96.52%, respectively. The mutation site analysis showed that it was completely consistent with the final consensus sequence of next generation sequencing (NGS). The results showed that the combination of LSK112 kit and flow cell R10.4 allowed rapid whole-genome sequencing of SARS-CoV-2 without the need for verification of NGS.